STOCK TITAN

Vir Biotechnology, Inc. - VIR STOCK NEWS

Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.

Vir Biotechnology, Inc. (Nasdaq: VIR) is a prominent immunology company pioneering the use of advanced technological innovations to address some of the globe's most challenging infectious diseases. Combining leading scientific expertise with management prowess, Vir Biotechnology focuses on creating solutions for diseases that currently have inadequate or non-existent treatments.

Vir's core business revolves around leveraging breakthroughs in immune programming to manipulate pathogen-host interactions effectively. The company employs a multi-program, multi-platform approach, guided by rigorous science and driven by significant medical needs. Its technology platforms comprise antibodies, T cells, innate immunity, and small interfering ribonucleic acid (siRNA).

The company's product pipeline targets severe infectious diseases, including hepatitis B (HBV), influenza A, human immunodeficiency virus (HIV), and tuberculosis (TB). Vir's revenue streams come from various sources, including collaboration revenue, contract revenue, grant revenue, and license revenue.

Vir's strategy includes internal development, collaborations, and acquisitions, positioning itself as a leader in the biotech space. Notably, Vir's recent collaboration with Brii Biosciences has led to significant advancements in the pursuit of a functional cure for HBV. Through this partnership, they have achieved Breakthrough Therapy Designations for BRII-877 and BRII-835, investigational treatments targeting HBV and chronic hepatitis D virus (HDV) infections.

The company's latest achievements highlight its focus on developing effective therapeutic regimens for chronic HBV infection, a disease affecting over 254 million people globally. With ongoing clinical trials and a commitment to scientific excellence, Vir Biotechnology is at the forefront of transforming the treatment landscape for infectious diseases.

Rhea-AI Summary

Vir Biotechnology (Nasdaq: VIR) will host its 2022 Annual General Meeting (AGM) on May 20, 2022, at 11:30 a.m. PT, in a virtual format. Stockholders of record as of March 28, 2022, can participate by accessing the meeting via a provided online link. The virtual access will open at 11:15 a.m. PT. Investors are encouraged to vote and submit proxies ahead of the meeting, utilizing instructions from the proxy materials. Vir focuses on immunologic treatments for infectious diseases, including COVID-19 and hepatitis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.78%
Tags
none
-
Rhea-AI Summary

Vir Biotechnology reported significant financial results for Q1 2022, with $1.2 billion in collaboration revenue driven by sotrovimab distribution. The company's cash reserves exceeded $2.5 billion, ensuring adequate funding for upcoming clinical trials targeting COVID-19, hepatitis B, hepatitis D, and influenza. Encouraging initial data from the MARCH trial suggests promising efficacy of VIR-2218 and VIR-3434 in treating hepatitis B. However, the FDA de-authorized sotrovimab's use in the U.S. due to the Omicron BA.2 variant's prevalence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
-
Rhea-AI Summary

Vir Biotechnology announced a virtual R&D Day focusing on its hepatitis B and D pipeline, scheduled for April 27, 2022, at 12:00 pm ET. The company will present initial data from the MARCH trial for treatment combinations of VIR-2218 and VIR-3434, reporting no drug-related safety signals. Additionally, a new program for chronic hepatitis D will be introduced. Key milestones for 2022 include further data on various trials for hepatitis B treatments. The company emphasizes a strong commitment to addressing the urgent public health challenges posed by chronic hepatitis B and D.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
none
Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) will provide a corporate update and report its financial results for Q1 2022 on May 5, 2022, after market close. Investors can access the results via a press release on the Vir website. The company focuses on immunologic therapies against infectious diseases, utilizing advanced technologies to boost the immune response. Its product pipeline includes candidates for COVID-19, hepatitis B, influenza A, and HIV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
-
Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) will host a virtual Hepatitis Portfolio R&D Day on April 27, 2022, from 12:00 – 2:00 p.m. ET. The event aims to showcase the company's hepatitis pipeline and clinical advancements for 2022. Key presentations will be made by senior leaders, including George Scangos, Phil Pang, and Carey Hwang, along with a hepatitis treatment overview by Dr. Jordan Feld. Participants can register and access a live webcast on Vir's website, which will be available for 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.24%
Tags
conferences
-
Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) announced that its scientists won the Pediatric COVID-19 Data Challenge, organized by BARDA and HHS. They developed a machine learning model to identify severe outcomes in pediatric COVID-19 patients using a dataset from over 116,000 pediatric outpatients. The award included a $200,000 prize, showcasing Vir’s commitment to leveraging AI for healthcare improvements. CEO George Scangos highlighted the significance of this achievement in enhancing patient care and pandemic preparedness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
covid-19
Rhea-AI Summary

Vir Biotechnology, Inc. (Nasdaq: VIR) will participate in a fireside chat at the 21st Annual Needham Healthcare Conference on April 11, 2022, at 11:00 a.m. ET. The conference will be held virtually, and investors can access a live webcast of the discussion on the Vir website under the Events & Presentations section. The recording will be available for 30 days. Vir Biotechnology focuses on leveraging immunologic insights and technology to combat serious infectious diseases, with a development pipeline that includes COVID-19, hepatitis B virus, influenza A, and HIV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.49%
Tags
conferences
-
Rhea-AI Summary

Vir Biotechnology and GlaxoSmithKline announced that the FDA amended the Emergency Use Authorization for sotrovimab, indicating its 500 mg dose is unlikely to work against the Omicron BA.2 variant. The companies are preparing data to support a higher dose and will engage with global health authorities. The FDA's update excludes sotrovimab in areas where infections are likely due to non-susceptible variants. Sotrovimab remains authorized in various countries, but its usage is limited based on variant susceptibility and hospitalizations related to COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
-
Rhea-AI Summary

Vir Biotechnology will participate in a panel discussion on infectious diseases at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 10:30 a.m. ET. The event will be held virtually, and a live webcast can be accessed through the Investors section of the Vir website, where it will also be archived for 30 days.

Vir Biotechnology focuses on developing treatments for serious infectious diseases using innovative immunologic technologies. Its pipeline includes candidates for COVID-19, hepatitis B, influenza A, and HIV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
conferences
Rhea-AI Summary

Vir Biotechnology reported transformative advancements in its fourth quarter and full-year 2021 results, revealing a substantial collaboration revenue of $917.2 million from the sale of sotrovimab, with 1.7 million doses sold globally to date. The company anticipates an additional $1.1 billion in revenue from contracts for upcoming deliveries in early 2022. Efforts for various ongoing trials regarding hepatitis B, HIV, and flu treatments are also highlighted, alongside a strong cash position of approximately $909.5 million, providing flexibility for future investments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags

FAQ

What is the current stock price of Vir Biotechnology (VIR)?

The current stock price of Vir Biotechnology (VIR) is $12.48 as of January 9, 2025.

What is the market cap of Vir Biotechnology (VIR)?

The market cap of Vir Biotechnology (VIR) is approximately 1.7B.

What is Vir Biotechnology, Inc.?

Vir Biotechnology, Inc. (Nasdaq: VIR) is an immunology company focused on combining advanced technologies to treat and prevent serious infectious diseases, including HBV, influenza A, HIV, and TB.

What are the main focus areas of Vir Biotechnology?

Vir Biotechnology focuses on developing treatments for severe infectious diseases by leveraging antibodies, T cells, innate immunity, and siRNA technology platforms.

How does Vir Biotechnology generate its revenue?

Vir Biotechnology generates revenue through collaborations, contracts, grants, and licenses.

What recent achievements has Vir Biotechnology accomplished?

Vir, in collaboration with Brii Biosciences, has received Breakthrough Therapy Designations for BRII-877 and BRII-835, investigational treatments for HBV and HDV infections.

What diseases are targeted by Vir's product pipeline?

Vir's product pipeline targets hepatitis B (HBV), influenza A, human immunodeficiency virus (HIV), and tuberculosis (TB).

What is the significance of Vir's collaboration with Brii Biosciences?

The collaboration has led to significant advancements in developing functional cure regimens for HBV, evidenced by their recent Breakthrough Therapy Designations.

How does Vir's technology platform work?

Vir utilizes immune programming to manipulate pathogen-host interactions, employing antibodies, T cells, innate immunity, and siRNA to develop effective treatments.

What are some characteristics of BRII-877 and BRII-835?

BRII-877 is a monoclonal antibody targeting HBV and HDV, while BRII-835 is an siRNA targeting HBV and HDV with enhanced stability and antiviral activity.

How does Vir approach treatment for chronic HBV infection?

Vir is conducting clinical trials and planning multiple combination studies to optimize curative regimens for broader HBV patient populations in partnership with Brii Biosciences.

What impact does Vir aim to have on global infectious disease treatment?

Vir aims to transform the treatment landscape for severe infectious diseases by developing innovative, effective therapeutic options through advanced scientific research and collaborations.
Vir Biotechnology, Inc.

Nasdaq:VIR

VIR Rankings

VIR Stock Data

1.72B
117.09M
11.9%
74.31%
4.42%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN FRANCISCO